181 related articles for article (PubMed ID: 36043457)
21. Recent advances in the treatment of adult T-cell leukemia-lymphomas.
Utsunomiya A; Choi I; Chihara D; Seto M
Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
Int J Hematol; 2024 Jun; 119(6):736-744. PubMed ID: 38532079
[TBL] [Abstract][Full Text] [Related]
25. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
26. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
27. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
28. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
29. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
31. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
32. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.
Yonekura K; Kusumoto S; Choi I; Nakano N; Ito A; Suehiro Y; Imaizumi Y; Yoshimitsu M; Nosaka K; Ohtsuka E; Hidaka M; Jo T; Sasaki H; Moriuchi Y; Ogata M; Tatetsu H; Ishitsuka K; Miyazaki Y; Ueda R; Utsunomiya A; Ishida T
Blood Adv; 2020 Oct; 4(20):5133-5145. PubMed ID: 33091125
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
[TBL] [Abstract][Full Text] [Related]
34. [Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].
Fuji S
Rinsho Ketsueki; 2018; 59(4):426-431. PubMed ID: 29743403
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Nosaka K; Kusumoto S; Nakano N; Choi I; Yoshimitsu M; Imaizumi Y; Hidaka M; Sasaki H; Makiyama J; Ohtsuka E; Jo T; Ogata M; Ito A; Yonekura K; Tatetsu H; Kato T; Kawakita T; Suehiro Y; Ishitsuka K; Iida S; Matsutani T; Utsunomiya A; Ueda R; Ishida T
Br J Haematol; 2022 Feb; 196(3):629-638. PubMed ID: 34632569
[TBL] [Abstract][Full Text] [Related]
36. Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.
Phillips AA; Harewood JCK
Curr Hematol Malig Rep; 2018 Aug; 13(4):300-307. PubMed ID: 30047026
[TBL] [Abstract][Full Text] [Related]
37. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
38. Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
Morichika K; Tomoyose T; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Nishi Y; Nakachi S; Karube KN; Fukushima T; Katoh T; Ohshima K; Masuzaki H
Intern Med; 2016; 55(10):1345-9. PubMed ID: 27181545
[TBL] [Abstract][Full Text] [Related]
39. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ΞΆ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
40. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Blood Adv; 2020 May; 4(10):2180-2191. PubMed ID: 32433748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
